Puma Biotechnology
PBYI
151 hedge funds and large institutions have $210M invested in Puma Biotechnology in 2025 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 14 closing their positions.
34,850% more call options, than puts
Call options by funds: $699K | Put options by funds: $2K
136% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 14
37% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 38
15% more capital invested
Capital invested by funds: $183M → $210M (+$27.7M)
14% more funds holding
Funds holding: 132 → 151 (+19)
1.89% more ownership
Funds ownership: 68.26% → 70.14% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.97M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.85M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.81M |
| 4 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
+$1.55M |
| 5 |
RWM
Ritholtz Wealth Management
New York
|
+$1.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$3.79M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$2.96M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.32M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.06M |
| 5 |
Universal-Beteiligungs- und Servicegesellschaft
Frankfurt Am Main,
Germany
|
-$845K |
PBYI Hedge Fund Activity: Q4 2025 in Review
151 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q4 2025, worth a combined $210M — up 15% from $183M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new PBYI positions and 14 closed out — a net gain of 19 holders — while 52 added to existing stakes and 38 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $2.97M. The largest seller was Russell Investments Group, cutting an estimated $3.79M.
- 151 institutional investors held Puma Biotechnology (PBYI) as of Q4 2025, up from 132 in Q3 2025.
- Funds reported $210M of Puma Biotechnology stock for Q4 2025, up 15% quarter-over-quarter.
- 33 funds opened new Puma Biotechnology positions in Q4 2025 and 14 closed out, a net change of +19 holders.
- The largest Puma Biotechnology buyer in Q4 2025 was Goldman Sachs, an estimated $2.97M added.
- The largest Puma Biotechnology seller in Q4 2025 was Russell Investments Group, an estimated $3.79M sold.
Based on aggregated 13F filings for Q4 2025.